Hume Care’s most consequential evidence gap is not a missing weight-loss percentage. It is the distance between what the homepage promises and what the contractual documents define. The marketing brings together personalized GLP-1 treatment, clinician access, body-composition tracking and a money-back promise. The terms separate the technology company from the medical network, limit how device data may influence care and describe a substantially narrower guarantee. Understanding those distinctions matters more than treating the package as one clinically validated intervention.
This review examines public documentation consulted October 19, 2026. It evaluates what Hume documents about its offering, not whether an individual should receive treatment. Hume is documented as offering access to GLP-1 care, but the reviewed material does not establish a product-by-product medication catalog or measured outcomes for the HumeCare+ program. Our approach to what provider documents can establish distinguishes contractual responsibilities and advertised features from evidence that a specific treatment or combined program produces a clinical benefit.
At a glance
- Who provides medical care
- Hume Health Care LLC describes itself as a technology and administrative platform; an independent clinical network handles evaluations, prescribing and ongoing clinical management.Sources: [6]
- Advertised starting price
- The homepage advertises a three-month plan starting at $199 per month with a $100 welcome credit, alongside $299. The promotion’s duration and effective three-month total are not established.
- Medication pathways
- The terms contemplate both FDA-approved branded GLP-1 medicines and compounded preparations, but the reviewed material does not identify a complete product, formulation or route-specific catalog.Sources: [6]
- Renewal and cancellation
- Membership renews automatically. Cancellation must be completed through designated channels at least 48 hours before renewal; prepaid periods do not receive prorated refunds.Sources: [6]
Start with the evidence behind the package
HumeCare+ is marketed as more than access to medication. The homepage describes physician-prescribed GLP-1 treatment, monthly body-composition scans, supportive therapies, continuous physician optimization and a connected app. It also advertises side-effect support, progress monitoring and guidance after medication ends. Those are descriptions of a service offering, not evidence that the combined package has been clinically tested. The consulted documentation does not establish a Hume-specific controlled study or independently measured program outcomes.
One particularly strong promotional claim concerns glycine, B12 and B6, which the homepage says are built into the protocol to protect muscle and ease side effects. The reviewed evidence does not verify those benefits for Hume’s particular offering or establish each component’s formulation, route or presentation. Readers should distinguish an ingredient’s presence in marketing from evidence supporting the exact combination being offered. The same distinction applies to the homepage’s claim that more than 20,000 Americans trust the service.
Published medication trials cannot close that provider-specific gap. Research on a defined drug, route and study population does not establish outcomes for Hume’s service, compounded preparations or vitamin combinations. Nor does a weight-loss guarantee function as a clinical result: it is a commercial promise with conditions. Our guide to why a clinical trial is not a company performance report explains the boundary. Hume’s documents are most useful here for understanding its operations and obligations, rather than predicting personal results.
| Topic | What is advertised or described | What needs clarification |
|---|---|---|
| Clinical care | Continuous physician optimization and clinician access | Which clinician handles follow-up and what response time applies |
| Medication | Personalized GLP-1 treatment | Exact product, formulation, route and dispensing pharmacy |
| Starting price | From $199/month with a welcome credit | Promotion duration, checkout total and renewal price |
| Guarantee | 10% weight loss in six months on the homepage | How that promise relates to the conditional 90-day contractual guarantee |
| Body data | Connected tracking and body-composition scans | How wellness information is used without becoming a prescribing basis |
The company, medical network and pharmacy have different jobs
The contractual counterparty is Hume Health Care LLC, a Delaware limited liability company. Its terms explicitly say Hume does not practice medicine, employ physicians, prescribe medications or dispense drugs. Instead, evaluations, prescription decisions and ongoing clinical management belong exclusively to an independent third-party network of physicians. This is a meaningful distinction from reading the homepage’s treatment language as evidence that Hume itself delivers every part of care. The network’s licensing statements were not independently verified for this review.
Before accessing clinical services, users must separately accept the clinical network’s documents; Hume’s terms direct them to MD Integrations. The terms also point to a provider directory intended to list names, license numbers, license types and licensing states. Patients may review credentials before an encounter and decline a particular provider without losing platform access. Neither that directory nor the external clinical-network documents were consulted, so this review cannot assess their individual providers or additional contractual conditions.
Pharmacies hold another distinct role. The terms assign dispensing decisions to pharmacies and describe a choice among pharmacy partners. If a selected pharmacy becomes unavailable, Hume may facilitate an alternative connection, but it does not guarantee a particular pharmacy or medication. The consulted pages do not name the actual dispensing pharmacies or establish their accreditations. Before paying, a useful request is a written explanation of who handles clinical questions, fulfillment problems and any proposed pharmacy substitution.
Medication categories are documented; specific products are not
Hume’s terms describe two medication pathways. FDA-approved branded GLP-1 medicines may be prescribed by network physicians and filled through standard retail or mail-order pharmacies described as licensed. Separately, the terms contemplate custom-compounded GLP-1 preparations filled through compounding pharmacies. Neither pathway establishes a complete catalog in the reviewed material. Specific medicines, concentrations, presentations and administration routes remain unresolved; references to research or injection-tracking features should not be treated as proof that a particular product is offered.
For compounded preparations, Hume requires an independent physician determination that the formulation is appropriate to the individual’s circumstances. Its examples include documented previous GLP-1 use or a qualifying clinical condition, without presenting these as exhaustive criteria. The privacy policy also describes secondary screening that may ask about previous GLP-1 use, documented conditions, allergies and intolerances. Those statements establish a screening process, not that any one answer qualifies someone for a prescription or satisfies every clinical requirement.
FDA approval belongs to a specific product, not to Hume or a pharmacy. Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality; nonapproval alone does not prove clinical inequivalence. FDA recommends compounded drugs when a patient’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our guide to approved medicines and compounded preparations explains why exact product identification is essential to interpreting evidence.
Entry and state availability require a second look
The homepage offers a free online assessment advertised as taking one minute. General platform eligibility requires being at least 18, living in a supported state, having a compatible device and reliable internet, and satisfying any additional requirements the platform establishes. These are access conditions, not a complete clinical eligibility policy. The terms expressly say meeting them does not guarantee approval for clinical services or a prescription; suitability remains a decision for the independent network’s physicians.
State coverage is inconsistent across the consulted pages. The homepage names Louisiana and Mississippi as unavailable. The dedicated coverage page adds Alabama and Arkansas, while listing Alaska and Hawaii as served. The terms provide the broader boundary: services are available only in the United States and in states where the clinical network has licensed physician coverage. Someone in a state affected by the discrepancy should obtain confirmation before paying rather than assume the shorter exclusion list controls.
Other practical admission details remain undocumented in this record. The pages do not establish complete clinical inclusion and exclusion criteria, required laboratory testing, laboratory charges or a clinical-evaluation turnaround time. They also do not establish Spanish-language care, interpretation or specific accessibility arrangements. These gaps do not prove the services are unavailable; they identify questions that must be answered directly. A brief introductory questionnaire should not be mistaken for a documented, complete medical evaluation.
The starting price is not a complete treatment quote
The main offer is presented as a three-month plan that ships monthly. Its pricing block shows $299 alongside a starting price of $199 per month after a $100 welcome credit. It does not establish how long the discounted price lasts or the effective three-month total. Medical consultation and one-to-one doctor support are shown as free against promotional reference values of $60 and $99. The Hume Pod, app and shipping are also promoted as free, with reference values of $352 and $49 for the first two.
The terms describe a self-pay membership covering platform access, clinical consultations and medication when prescribed and fulfilled through Hume’s pharmacy partners. However, certain medicines, dosages, formulations or fulfillment options may incur additional charges disclosed at fulfillment. That qualification matters: the membership is not an unconditional promise that every medication choice costs the advertised starting amount. The pharmacy-partner requirement also means readers should not assume the same bundled pricing applies to any pharmacy they independently select.
Billing intervals may be monthly, quarterly, semiannual or annual, with the checkout displaying the price and any prepaid total. These are possible arrangements, not proof that every member must prepay three months. Hume says it is not enrolled with Medicare, Medicaid or other government healthcare programs, and its current membership prohibits seeking or accepting reimbursement from health insurance or public programs, including TRICARE and Veterans Affairs benefits. The homepage separately advertises FSA/HSA reimbursement eligibility; that should not be read as health-insurance coverage or an individual tax determination.
Two refund stories need reconciliation before enrollment
The homepage’s most prominent outcome promise is losing at least 10% of body weight in six months or receiving money back. It also advertises a 90-day money-back guarantee. The contractual provision is different: eligible members who complete participation requirements and achieve no measurable weight loss during the initial 90 days may request membership-fee refunds, excluding clinical consultation fees assessed at enrollment and each refill. Those fees also need explanation because the promotional pricing block presents consultation as free.
The contractual guarantee excludes anyone who has previously used any GLP-1 medicine, compounded or branded. It applies only to first-time members during their initial 90-day membership, not renewals, restarts or transfers. Requirements include all 13 weekly Hume Pod weigh-ins logged in the app, following documented clinical recommendations and remaining an active, paying member through the guarantee period without voluntary cancellation or suspension. This is substantially narrower than a general promise of satisfactory results or a refund whenever treatment disappoints.
A guarantee request must be submitted within 14 days after the period ends. Verification may take up to two weeks, followed by refund issuance within 10 business days after verification; bank receipt is not guaranteed within that interval. A separate provision promises an automatic membership-fee refund within 10 business days if the initial evaluation finds the member ineligible for any treatment. An included device must be returned in original condition, or its cost is deducted. Neither provision resolves the conflicting six-month advertising promise.
Follow-up and delivery claims need operational detail
Hume advertises unlimited clinician access around the clock, side-effect support and continuous physician optimization. These are potentially useful features, but availability language does not establish an individual response-time commitment, a specific encounter format or a documented escalation process. The reviewed material does not explain how frequently a member receives a substantive clinical reassessment. NIDDK describes follow-up as involving treatment response and tolerability, not merely continued payment; our guide to clinical follow-up beyond renewal notices develops that distinction.
The homepage also advertises free next-day delivery, while the plan description says shipments occur monthly. Those statements do not establish the operational cutoff, whether the timing runs from prescription approval or dispatch, or which destinations qualify. The consulted documentation does not explain cold-chain procedures, delayed-package handling or replacement terms. If an injectable GLP-1 shipment arrives warm or insufficiently refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy to resolve the concern.
Membership itself renews automatically at the then-current price. Prepaid plans receive an emailed reminder at least seven days before renewal, according to the terms. Cancellation is available through Account, then Subscription, in the web application or by emailing support@humecare.com, and must be completed at least 48 hours before renewal to avoid another charge. Canceling a prepaid term preserves access until its end but does not produce a prorated refund. The homepage’s “cancel anytime” message should be understood alongside those deadlines.
Connected tools are not validated clinical decision systems
Hume’s device-and-app integration is a prominent differentiator, but its terms place a firm boundary around device information. Such data is informational only and may not be relied upon by network clinicians for diagnosis, prescribing decisions or medication dosing. That contractual limit should temper interpretations of marketing that links body changes with personalized treatment. Tracking can be part of the documented service without establishing that a consumer measurement is a validated basis for a clinical decision.
The privacy policy says Hume Care is not a HIPAA-covered entity. It characterizes adopting practices that meet or exceed HIPAA standards as the company’s voluntary commitment, not evidence of covered-entity status. Wellness data from Hume Health does not automatically flow into Hume Care: sharing requires user-initiated account linking and permission settings. Readers should therefore evaluate both the privacy commitment and their actual sharing choices, rather than assume all connected services have identical responsibilities or access.
The policy also limits Pro.f to a supporting role in consultation preparation. It does not diagnose, recommend treatment or dose changes, make autonomous clinical decisions, or transmit information into the clinician’s record on the user’s behalf. That last limitation is practical: preparing information in a tool is not confirmation that the treating clinician received it. The consulted terms and privacy texts also contained omitted intermediate material, so this review cannot claim to cover every provision governing the platform or its data practices.
Questions & answers
Does Hume itself prescribe GLP-1 medication?
No. Hume Health Care LLC says it operates the technology and administrative platform and does not prescribe or dispense medication. Its terms assign evaluation, prescribing and ongoing clinical management to an independent physician network. Users must separately accept that network’s documents. The provider directory and external clinical-network documents were not consulted for this review, so individual credentials were not verified.
Which medication would I receive through HumeCare+?
The reviewed documents do not answer that at a product-specific level. They contemplate branded FDA-approved GLP-1 medicines and compounded preparations, subject to independent prescribing and pharmacy availability. Before enrollment, ask for the exact medicine, formulation, route, presentation and dispensing pharmacy, plus any separate charge. Hume does not guarantee prescription approval, a particular medicine or a specific pharmacy.
Is the $199 monthly price the full ongoing cost?
It is an advertised starting price associated with a $100 welcome credit, not a documented universal renewal price. The promotion’s duration and effective three-month total remain unclear. Membership includes consultations and qualifying pharmacy-partner medication fulfillment, but the terms allow additional charges for some medication or fulfillment choices. Check the actual billing interval, amount collected, later renewal price and potential extras before authorizing payment.
Can previous GLP-1 users receive the money-back guarantee?
The contractual 90-day guarantee excludes anyone who has used any GLP-1 medicine previously, whether branded or compounded. That is separate from treatment eligibility: previous use appears among circumstances considered in compounded-treatment screening. The guarantee also requires first-time membership, all 13 weekly logged weigh-ins and other participation conditions. Ask Hume to reconcile that provision with the homepage’s separate six-month, 10% weight-loss promise in writing.
How do I stop a Hume renewal?
Use the web application’s Account and Subscription section or contact support@humecare.com. The terms require cancellation to be completed at least 48 hours before the next renewal date. Retain confirmation rather than treating an unfinished request as completed cancellation. For prepaid membership, access continues through the paid term, but there is no prorated refund or refund for a partially used period.
Does linking Hume wellness data let the app manage treatment?
No such role is established. Sharing between Hume Health and Hume Care requires user initiation and permissions; it is not automatic. Device data is contractually limited to informational, nondiagnostic use and cannot be relied upon for prescribing or dosing. Pro.f also does not recommend treatment changes or automatically transmit information into the clinician’s record. Ask how relevant information actually reaches the treating clinician.
Our assessment
Hume documents a recognizable GLP-1 access model with independent physician care, partner-pharmacy fulfillment, connected wellness tools and a self-pay membership. Its terms provide useful clarity about divided responsibilities and the limits of device data. They do not establish clinical effectiveness for the HumeCare+ package or validate the advertised benefits of its supportive ingredients. The most important unresolved issues are concrete: the actual product and pharmacy, full checkout and renewal charges, inconsistent state coverage, and the conflict between the homepage’s outcome promise and the narrower contractual guarantee. Before committing, obtain those answers in writing, including which refund provision applies and whether any consultation charge remains excluded. Hume’s documentation supports evaluating it as an access-and-support service, not treating its commercial promises as a substitute for product-specific clinical evidence.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Hume Care / HumeCare+ — coverage ↗
- Hume Care / HumeCare+ — terms conditions ↗
- Hume Care / HumeCare+ — official website ↗
- Hume Care / HumeCare+ — privacy policy ↗